PROPHYLAXIE DE LA FIBRILLATION VENTRICULAIRE PRIMAIRE A LA PHASE AIGUE DE L'INFARCTUS AIGU DU MYOCARDE

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Effect of oral sustained-release nitroglycerin on exercise capacity in angina pectoris: Dose-response relation and duration of action during double-blind crossover randomized acute therapy

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Controversial aspects of physical training in patients with COPD

Physical rehabilitatiaon has tremendous implication for the patient with chronic obstructive pulmonary disease, including clinical and psychological improvement. The authors of this article discuss the pathophysiological factors of physical rehabilitation and include recommendations for developing such a program.SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe

Oral sustained-release nitroglycerin in chronic stable angina: A multicenter, double-blind, randomized crossover trial

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

EFFETS HEMODYNAMIQUES DE LA NITROGLYCERINE MICROENCAPSULEE A LIBERATION PROLONGEE DANS L'INFARCTUS AIGU DU MYOCARDE

The hemodynamic effects following an oral dose of 19.5 mg of nitroglycerine microencapsulated to give prolonged release have been studied in 10 patients during the 48 hours which followed the establishment of a myocardial infarct complicated by moderate left cardiac insufficiency. The right auricular pressure and the pulmonary capillary pressure diminished significantly 20 minutes after the dose; 4 hours later the persistence of these effects is significant. A transient diminution of the systolic arterial pressure was observed initially (p < 0.05). We observed that the cardiac index tends to increase although the increase did not attain the threshold of significance. No difference was observed in cardiac frequency, diastolic and mean arterial pressure or in the sytemic vascular resistance. We conclude that in the patient presenting an acute myocardial infarct, 19.5 mg of NTG, microencapsulated to give prolonged release, essentially produces a reduction of the preload, with an early onset of action and a hemodynamic efficacy lasting at least 4 hours.SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe

Acute and chronic hemodynamic effects of Enalapril in patients with congestive heart failure

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Effects of molsidomine on left ventricular dimensions and cardiac function in patients with chronic heart failure

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

VERGLEICH DER WIRKUNGEN VON NITRATEN, MOLSIDOMIN UND DEM MOLSIDOMIN-METABOLITEN SIN-1 BEI DER AKUTEN KORONARINSUFFIZIENZ

In a study on 15 patients suffering from acute angina pectoris the influence of SIN-1, administered intracoronarily, on the tone of the coronary arteries and the hemodynamics of the general circulation has been tested. In this connection a significant dilation of the coronary lumina occurred in all vessel sections, also in the region of the stenosis. The effect on the distal vessel section was stronger than that on the proximal section. Heart frequency and blood pressure remained unaffected. It was possible to prevent ergonovin-induced vessel spasms with a previously administered SIN-1 injectionSCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe

Effect of bopindolol on circadian variations in heart rate and on exercise testing

The effects of a single oral dose of 4-mg bopindolol were studied in eight patients in a single-blind placebo-controlled study. Continuous electrocardiogram recordings made over 72 hours after drug administration showed that bopindolol had no effect on minimal heart rate, but reduced maximal heart rate significantly (P < 0.005) for at least 48 hours after treatment. During exercise to 60 watts, bopindolol significantly reduced exercise-induced tachycardia for up to at least 72 hours posttreatment (P < 0.05). At this mild level of exercise in patients with stable angina pectoris no statistically significant effect on systolic and diastolic blood pressure was demonstrated. We conclude that bopindolol is a long-acting beta-receptor antagonist with moderate intrinsic sympathomimetic activity.SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe

Clinical and hemodynamic observations on orally administered sulmazol (ARL115BS) in refractory heart failure

SCOPUS: ar.jinfo:eu-repo/semantics/publishe